Literature DB >> 26002608

An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer.

Y Togashi1, H Mizuuchi2, Y Kobayashi2, H Hayashi1, M Terashima1, K Sakai1, E Banno1, T Mizukami1, Y Nakamura1, M A de Velasco1, Y Fujita1, S Tomida1, T Mitsudomi2, K Nishio3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26002608     DOI： 10.1093/annonc/mdv240

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

Review 1.  Tackling ALK in non-small cell lung cancer: the role of novel inhibitors.

Authors:  Francesco Facchinetti; Marcello Tiseo; Massimo Di Maio; Paolo Graziano; Emilio Bria; Giulio Rossi; Silvia Novello
Journal:  Transl Lung Cancer Res       Date:  2016-06

2.  Targeting ALK in Neuroendocrine Tumors of the Lung.

Authors:  Dilara Akhoundova; Martina Haberecker; Ralph Fritsch; Sylvia Höller; Michael K Kiessling; Markus Rechsteiner; Jan H Rüschoff; Alessandra Curioni-Fontecedro
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

3.  Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?

Authors:  Eri Banno; Yosuke Togashi; Yu Nakamura; Masato Chiba; Yoshihisa Kobayashi; Hidetoshi Hayashi; Masato Terashima; Marco A de Velasco; Kazuko Sakai; Yoshihiko Fujita; Tetsuya Mitsudomi; Kazuto Nishio
Journal:  Cancer Sci       Date:  2016-07-14       Impact factor: 6.716

4.  ARID1B alterations identify aggressive tumors in neuroblastoma.

Authors:  Soo Hyun Lee; Jung-Sun Kim; Siyuan Zheng; Jason T Huse; Joon Seol Bae; Ji Won Lee; Keon Hee Yoo; Hong Hoe Koo; Sungkyu Kyung; Woong-Yang Park; Ki W Sung
Journal:  Oncotarget       Date:  2017-07-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.